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Abstract 
Background: The COVID-19 pandemic has led highly developed healthcare systems to the brink of collapse due to 
the large numbers of patients being admitted into hospitals. One of the potential prognostic indicators in patients 
with COVID-19 is frailty. The degree of frailty could be used to assist both the triage into intensive care, and decisions 
regarding treatment limitations. Our study sought to determine the interaction of frailty and age in elderly COVID-19 
ICU patients.
Methods: A prospective multicentre study of COVID-19 patients ≥ 70 years admitted to intensive care in 138 ICUs 
from 28 countries was conducted. The primary endpoint was 30-day mortality. Frailty was assessed using the clinical 
frailty scale. Additionally, comorbidities, management strategies and treatment limitations were recorded.
Results: The study included 1346 patients (28% female) with a median age of 75 years (IQR 72–78, range 70–96), 
16.3% were older than 80 years, and 21% of the patients were frail. The overall survival at 30 days was 59% (95% CI 
56–62), with 66% (63–69) in fit, 53% (47–61) in vulnerable and 41% (35–47) in frail patients (p < 0.001). In frail patients, 
there was no difference in 30-day survival between different age categories. Frailty was linked to an increased use of 
treatment limitations and less use of mechanical ventilation. In a model controlling for age, disease severity, sex, treat-
ment limitations and comorbidities, frailty was independently associated with lower survival.
Conclusion: Frailty provides relevant prognostic information in elderly COVID-19 patients in addition to age and 
comorbidities.
Trial registration Clinicaltrials.gov: NCT04 321265, registered 19 March 2020.
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Introduction
The first wave of the SARS-CoV-2 coronavirus dis-
ease (COVID-19) pandemic disproportionally affected 
the elderly population, creating an unprecedented 
influx of patients into hospital and intensive care [1]. 
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Consequently, ICU capacity had to be increased several 
fold [2]. Despite this, many countries struggled with lim-
ited resources and were forced into a stricter admission 
policy to ICUs. For various reasons, this disproportion-
ately affected the very old subgroup of patients, with 
reports of ad hoc criteria used for ICU admission, some 
even based on age alone.
Over the last few years, the assessment of frailty at 
admission to the ICU has become increasingly popu-
lar. The clinical frailty scale (CFS) proved to be a useful 
tool in predicting the chances of ICU survival in very old 
intensive care patients [3–5] and is one of a number of 
tools commonly used to assess frailty. In previous studies, 
the CFS demonstrated a high inter-rater reliability [6].
Indeed, the UK National Institute for Health and 
Care Excellence (NICE) advocates the use of the CFS 
in clinical decision making for patients with COVID-19 
≥ 65 years [7]. Additionally, during the present COVID-
19 pandemic frailty has been found to be strongly asso-
ciated with all-cause mortality risk in hospitalised older 
patients [8, 9]. Hewitt et  al. showed in a study of 1564 
adult (> 18  years) COVID-19 patients that frailty was 
a better tool for risk stratification than age or concomi-
tant diseases [10]. In another, smaller study of 677 older 
(> 65 years) patients with COVID-19, frailty was associ-
ated with mortality after a mean follow-up of 34 days [8]. 
A similar association between frailty and hospital mor-
tality was shown in a smaller cohort of 42 COVID-19 
patients [9]. Bellelli et al. also demonstrated in a cohort of 
105 patients that frailty could be used for risk evaluation 
of COVID-19 and proposed the systematic collection of 
frailty in all patients at hospital admission [11]. By con-
trast, recently published retrospective studies focusing 
on non-ICU COVID-19 patients found that frailty had 
no or low diagnostic or prognostic value [12, 13]. There 
is therefore need for more high-quality data on patient 
outcomes to determine whether frailty, as assessed by 
the CFS, and in particular its interaction with age can be 
used for prognostication in critically ill elderly patients 
with COVID-19 [14]. This is of paramount importance 
in order to establish an ethical and medically appropriate 
rationing of ICU care.
The main aim of the present study was to study the out-
come of elderly patients with COVID-19 admitted to an 




This is a prospective multicentre study of COVID-19 
patients ≥ 70 years old admitted to the ICU. Recruitment 
took place from 19 March to 26 May 2020, in 138 inten-
sive care units in 28 countries (for a list of collaborators, 
see Additional file  1, for a map of participating ICUs 
and patients included see Additional file  2). The study 
was planned and conducted by the very old intensive 
care patients (VIP) project within the European Society 
of Intensive Care Medicine (ESICM) (www. vipst udy. org) 
who also endorsed the study. National coordinators were 
responsible for the recruitment of ICUs, coordinated 
national and local ethical permission and supervised 
patient recruitment at the national level. Ethical approval 
was mandatory for study participation in each coun-
try. Due to the diversity of ethical consent procedures, 
some countries could recruit patients without informed 
consent while the rest had to obtain it. The study delib-
erately allowed for co-enrolment of study patients to 
additional observational COVID-19 studies. To limit 
workload, screening failures for the study were not 
recorded. The study was registered on ClinicalTrials.gov 
(ID: NCT04321265) and adhered to the European Union 
General Data Privacy Regulation (GDPR) directive, 
which is implemented in most participating countries.
It was agreed that the first period of the COVIP study 
would stop on 26th of May 2020 corresponding with the 
slowing down of the first wave of critically ill patients in 
most of the participating countries. However, the study 
continued to recruit in order to catch a possible second 
wave. The present study included patients from the first 
recruitment period. Each participating ICU included 
consecutive patients up to and including those admitted 
on 26th of May 2020. COVID-19 diagnosis was based on 
a positive polymerase chain reaction (PCR) test. Patients 
were followed up until death, 30 days, and three months 
after ICU admission. Similar to the previous VIP studies, 
a website was set up to facilitate dissemination of infor-
mation about the study and to allow for data entry using 
an electronic case report form (CRF).
Study population
Patients who were 70 years or older with proven COVID-
19 and admitted to an ICU were eligible. Pre-ICU triage 
was not a part of this study. To avoid duplication caused 
by the transfer of a patient from one ICU to another, 
each patient could only be entered once into the database 
regardless of readmission, transfer or other reason. This 
resulted in a single electronic CRF per patient. The refer-
ence date was day 1 of the first admission to an ICU. All 
consecutive dates were numbered sequentially from the 
admission date.
Data collection
Centres collected the data using a uniform online CRF. 
The sequential organ-failure assessment (SOFA) score 
on admission was calculated either manually or using 
an online calculator in the electronic CRF as described 
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previously [3, 4]. Additionally, the first arterial blood gas 
analysis with  pO2 [mmHg] and the  FiO2 [%] to calculate 
the  PaO2/FiO2 index  (pO2/FiO2 ratio) on admission was 
recorded. Length of stay (LOS) was recorded in hours. As 
described previously, [3] the electronic CRF and database 
ran on a secure server set up by and stored at Aarhus 
University, Aarhus, Denmark.
Frailty and comorbidities
The frailty level prior to the acute illness and hospital 
admission was assessed using the clinical frailty scale 
(CFS). This is an intuitive pictographic description along 
with information required to perform the assessment 
[15]. The CFS defines nine classes from very fit to ter-
minally ill (Additional file  3). The required information 
could be obtained either from the patient, the caregiver/
family or hospital records [4, 16]. We used the English 
version of the CFS. Patients with a CFS of 1–3 were clas-
sified as fit, those with a CFS of 4 as vulnerable and a CFS 
of 5 or higher as frail. CFS assessment was performed as 
described previously with excellent inter-rater variation 
[4]. The definitions of pre-existing comorbidities are pro-
vided in Additional file  4.
Outcome measurement
The primary endpoint was the survival status assessed 
at 30 days after ICU admission. The outcome at 90 days 
was also assessed. Data could be retrieved either directly, 
from the hospital administration system or following tel-
ephone follow-up. Limitation of life-sustaining therapies 
such as withholding or withdrawing organ support was 
documented based on international recommendations 
[17] although there is a large variation in Europe in the 
use of end-of-life care [16]. The definitions of organ sup-
port are detailed in Additional file  5.
Statistical analysis
No formal sample size calculation prior to this purely 
observational study was performed. The analysis plan 
was finalised prior to any analysis. The primary exposure 
was frailty (fit, vulnerable or frail at ICU admission), the 
primary outcome was 30-day survival, and the secondary 
outcomes were overall survival up to 90  days after ICU 
admission, organ support (vasoactive drugs, mechanical 
ventilation, non-invasive ventilation and renal replace-
ment therapy) and treatment limitation. Group com-
parisons for continuous variables were performed using 
the Kruskal–Wallis test if no-normally distributed, and 
ANOVA if normally distributed; for categorical vari-
ables the Chi square test was used. Overall survival from 
ICU admission was estimated using the Kaplan–Meier 
method. If lost to follow-up at 90 days, patients were cen-
sored at 30 days or ICU discharge if status at 30 days was 
unknown. Survival between groups was compared using 
the log-rank test. Incidence of organ support and treat-
ment limitation were estimated using cumulative inci-
dence analysis considering ICU death and ICU discharge 
as competing risks. Comparisons between groups were 
performed using Gray’s test.
Multivariate analysis of primary and secondary out-
comes: to account for the multilevel structure of the data 
with individuals nested into the ICU, all multivariate 
models were built including a random intercept by ICU, 
assuming a Gaussian distribution for the random effect. 
The random effect was tested by comparing log-likeli-
hood of two models including frailty with and without 
random effect.
Three sequential random effects, multilevel Cox regres-
sion models, were used to evaluate the impact of frailty 
on both 30-day and 90-day survival. First, we estimated 
the impact of frailty on outcome without adjustment for 
confounding using a baseline model including only frailty 
(model 1). Second, to estimate the impact of frailty when 
adjusting for patients’ baseline characteristics, the fol-
lowing covariates were added to model 1: age (as a con-
tinuous variable), sex, comorbidities, SOFA score, BMI, 
 PaO2/FiO2 (as continuous variables). Third, to evalu-
ate whether the effect of frailty was independent of ICU 
management strategies, both organ support and treat-
ment limitation (model 3) were added to model 2 as time-
dependent covariates (variables start at 0 for all subjects 
and are recoded to 1 only when organ support is received 
or when limitation occurs). Two sequential random 
effects, multilevel cause-specific Cox regression mod-
els, were used to evaluate the impact of frailty on organ 
support and treatment limitation. First, we estimated the 
impact of frailty on variable of interest without adjust-
ment for confounding using a baseline model including 
only frailty (model 1). Second, to estimate the impact of 
frailty when adjusting for patients’ baseline character-
istics the following covariates were added to model 1: 
age (as a continuous variable), sex, comorbidities, SOFA 
score, BMI,  PaO2/FiO2 (as continuous variables).
A sensitivity analysis was conducted to investigate 
whether results differ including only European patients.
All p values were two-sided, and p < 0.05 was consid-
ered statistically significant. Statistical analyses were per-
formed with R 3.2.3 software packages (R Development 
Core Team, Vienna, Austria).
Results
This study included 1346 patients from 138 ICUs across 
28 countries. The median number of recruited patients 
per ICU was 7 (IQR 3–12). The study flow chart is illus-
trated in Additional file  6. Survival at 30 and 90, respec-
tively, was available in 97% and 90% of the cohort.
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Frailty was assessed by an ICU physician in 55%, by 
dedicated research staff in 21%, by an ICU nurse in 13%, 
and by other personnel in 11% of the cases. Further 
information for CFS assessment was provided by hospi-
tal records (51%), the family or caregivers (25%), by the 
patient (22%) and by other information (2%). Patients 
characteristics and outcome were similar whether CFS 
was rated by an ICU physician or other personal and 
whether the CFS was based on hospital records or other 
sources.
The median age of patients was 75 years (IQR 72–78, 
range 70–96. Median CFS was 3 (IQR 2–4) and 20.7% of 
the patients were frail (CFS ≥ 5). Only one patient had 
CFS 9 so this group was not further split. Further base-
line characteristics of the study population are given in 
Table 1.
The overall survival at 30 days was 59% (95% CI 56–62). 
Ninety-day survival was 52% and decreased with increas-
ing CFS as illustrated in Additional file  7. Numbers of 
deaths are reported in Additional file  8. Figure 1a shows 
the prognostic relevance of frailty in a survival analysis. 
Figure  1b illustrates the frailty category by age groups 
below and above 75 years. Of note, there is no difference 
between age groups in frail patients.
Survival at 30 days was 66% (63–69) in fit, 53% (47–61) 
in vulnerable and 41% (35–47) in frail patients. The differ-
ence persisted at 90 days with respective survival of 59% 
(56–63), 47% (40–55) and 33% (27–39) p < 0.001). Length 
of ICU stay for patients discharged alive was 15  days 
(IQR7.0–29.0) in fit, 10  days (IQR 5–21) in vulnerable 
and 6 days (IQR 3.0–13) in frail patients (p < 0.001).
Table  2 shows models revealing the association 
between frailty and outcome even after controlling for 
comorbidities and disease severity and treatment strate-
gies. Frailty was associated with increased use of treat-
ment limitations and reduction in respiratory support 
as shown in Fig.  2 (cumulative incidences in Additional 
file  9). The use of treatment limitations was significantly 
higher in frail patients compared to fit patients and vul-
nerable patients (20-day cumulative incidence was 26% 
(95% CI 23–29) for fit patients, 40% (33–47) for vulner-
able patients and 43% (95% CI 37–48) for frail patients 
(p < 0.001). The association between frailty and treat-
ment limitation remained statistically significant after 
Table 1 Patient characteristics of the study population
CFS clinical frailty scale, SOFA sequential organ failure assessment score, IQR inter-quartile range, BMI body mass index, PaO2 partial pressure of oxygen, FiO2 fraction of 
inspired oxygen
All patients Fit (CFS 1–3) Vulnerable (CFS: 4) Frail (CFS: 5–9)
n = 1346 n = 874 n = 193 n = 279
Female sex
 n (%) 381 (28) 209 (24) 64 (34) 108 (39)
Age
 Median (IQR) 75 (72–78) 74 (72–77) 76 (73–79) 78 (74–82)
Frailty score—CFS
 Median (IQR) 3 (2–4) 2 (2–3) 4 (4–4) 6 (5–7)
SOFA score
 Median (IQR) 6 (3–8) 5 (3–8) 6 (3–8) 6 (4–9)
BMI
 Median (IQR) 28 (25–31) 27 (25–30) 28 (25–31) 28 (24–31)
PaO2/FiO2 (mmHg), n (%)
  ≤ 100 485 (37) 319 (37) 65 (35) 101 (37)
  > 100–200 546 (41) 376 (43) 76 (40) 94 (34)
  > 200–300 173 (13) 111 (13) 25 (13) 37 (13)
  > 300 125 (9) 59 (7) 11 (12) 44 (16)
Comorbidities, n (%)
 Diabetes mellitus 471 (35) 240 (27) 89 (47) 142 (51)
 Ischemic heart disease 291 (22) 127 (14) 59 (31) 105 (39)
 Chronic renal insufficiency 211 (16) 77 (9) 31 (17) 103 (38)
 Arterial Hypertension 896 (67) 529 (61) 139 (73) 228 (82)
 Pulmonary disease 314 (24) 169 (20) 60 (32) 85 (31)
 Chronic heart failure 205 (15) 72 (6) 49 (26) 84 (32)
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adjustment for patient characteristics (aHR for frail vs fit 
patients 2.79 (95% CI 1.96–3.91, p < 0.001)).
A sensitivity analysis showed that the findings were 
similar when excluding patients from outside Europe 
(N = 158).
Discussion
Our study reveals three important findings in COVID-19 
patients. First, frailty is a useful tool to stratify the risk 
of death at one and three months after admission to the 
ICU, and frailty offers an important additional prognos-
tic information to the age in patients aging 70 and older. 
Second, outcome in terms of mortality in patients with a 
frailty level ≥ 5 is similar in patients across all age groups 
≥ 70 years. Third, frailty was also associated with less use 
of mechanical ventilation and a higher rate of treatment 
limitation.
Age is frequently associated with a higher rate of hos-
pitalisation, ICU admission and mortality in COVID-
19 patients [18–20]. The high risk of mortality in older 
patients together with constraints on ICU bed availability 
may raise the question of rationing ICU admissions. Age 
alone should not be used and may be considered ageist 
[16]. For this reason, other factors should be investigated. 
Frailty as assessed by the CFS is a good candidate as it 
has previously been found to be strongly associated with 
mortality and is easy to use in acutely ill patients.
Before the COVID-19 pandemic emerged, frailty was 
already established as an important factor for outcome, 
particularly in very old ICU patients. This was docu-
mented in large studies from Canada [21] and Europe, 
and also in a systematic review. As a result, frailty was 
suggested early on during the pandemic as a useful tool 
to assist guiding therapy. In the UK, NICE issued guide-
lines advocating the use of the CFS in patients above 
65  years to assist with decision making regarding ICU 
admission. Here, scores of five and above were thought to 
represent a worse prognosis in critically ill patients [22]. 
However, the evidence for using frailty was extrapolated 
from pre-pandemic data [23], and as a result, this guide-
line was heavily criticised for being based on insufficient 
data.
During this pandemic, there have been many discus-
sions about the care of the old and the very old critical 
ill patients. Frailty has been the focus in four studies. In 
a retrospective single-centre study from Italy with 105 
patients, the frailty index was found to be an independ-
ent predictor not only of in-hospital mortality but also 
for ICU admission. In another single-centre study from 
the UK of 215 hospitalised, non-ICU, patients both CFS 
and age were associated with mortality [24]. By con-
trast, in a larger study of 1071 hospitalised patients with 
COVID-19, CFS was not associated with mortality. To 
date, the largest investigation of frailty in COVID-19 
patients is a multicentre observational study from the 
Fig. 1 a Kaplan–Meier curve illustrating survival dependent on clinical frailty scale (CFS) category: fit, vulnerable and frail. b Patients were divided 
according to the age median (75 years) and survival was illustrated according to their frailty category
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UK and Italy involving 1564 patients from 11 hospitals. 
The study included all hospitalised patients ≥ 18 years 
admitted with COVID-19 during a defined period and 
therefore differs from the present study which included 
only patients ≥ 70 years. They found a large proportion 
of patients were frail (CSF ≥ 5 in 51.4%) and that dis-
ease outcome was better predicted by frailty, measured 
with the CFS, than either age or comorbidity alone.
The importance of chronological age in COVID-19 
has been extensively documented. In a retrospective 
case series, 1591 consecutive patients with a median 
age of 63  years were admitted to 72 Italian hospitals 
between February and March 2020 [18]. They found 
that patients with a median age of 63  years or more 
had a higher mortality than younger patients; they also 
required mechanical ventilation more frequently. This 
result was supported by another retrospective study 
from Germany in 10,021 hospitalised adult patients 
from 920 different hospitals [25]. Overall, patients aged 
80  years or older had the highest mortality of 72%. 
These two studies, however, focused on chronological 
age alone with no frailty assessment used for outcome 
prognostication.
The use of frailty in general, and CFS in particular, was 
the focus of a recent editorial in ICM published prior to 
the pandemic [26]. This suggested that risk stratification 
should not be based on age alone but should include a 
frailty assessment. They also stressed the role of putting in 
place a time limited trial of treatment on admission to ICU 
as mortality after ICU treatment in frail elderly patients 
remains high. Current and recent research has not proven 
the long-term benefit of frailty assessment in these patients. 
The role of frailty may therefore better inform best inter-
est decisions—i.e. whether burdens of ICU are more likely 
to outweigh benefits (or vice versa) but caution should be 
applied in excluding patients for ICU based on age/frailty 
status alone as there may be some patients denied ICU that 
still have the potential to benefit despite being frail.
The present research has several strengths [27]. It is a 
multicentre trial that recruited patients from 28, mainly 
European, countries. It included different types of hospitals 
thus reflecting diverse health care systems underlining the 
Table 2 Three sequential random effects and multilevel Cox regression models were used to evaluate the impact of frailty on both 
30-days survival
First, we estimated the impact of frailty on outcome without adjustment on confounding using a baseline model including only frailty (model 1). Second, to estimate 
the impact of frailty when adjusting on patients’ baseline characteristics the following covariates were added to model 1: age, sex, comorbidities, SOFA score, BMI, 
 PaO2/FiO2. Third, to evaluate whether the effect of frailty was independent of ICU management strategies, both organ support and treatment limitation (model 3) 
were added to model 2 as time-dependent covariates. For all outcomes, significance of the random centre effect was tested comparing the likelihood of two models 
including frailty with and without random effect. Random effect was significant for all outcomes. No violation of the proportional hazard assumption was detected in 
the models
Model 1 unadjusted HR 
(95% CI)
p value Model 2 adjusted HR 
(95% CI)
p value Model 3 adjusted HR 
(95% CI)
p value
Survival at 30 days
 Vulnerable versus fit 1.75 (1.35–2.25)  < 0.001 1.55 (1.14–2.10) 0.011 1.14 (0.79–1.65) 0.4811
 Frail versus fit 3.20 (2.56–4.13)  < 0.001 2.41 (1.77–3.27)  < 0.001 1.86 (1.36–2.52)  < 0.001
Treatment limitation
 Vulnerable versus fit 2.26 (1.73–2.96)  < 0.001 1.7 (1.21–2.38) 0.0021
 Frail versus fit 3.98 (3.08–5.21)  < 0.001 2.79 (1.96–3.91)  < 0.001
Mechanical ventilation
 Vulnerable versus fit 0.83 (0.67–1.01) 0.055 0.92 (0.73–1.16) 0.5
 Frail versus fit 0.75 (0.62–0.92) 0.005 0.69 (0.54–0.87) 0.0043
Non-invasive ventilation
 Vulnerable versus fit 1.58 (1.11–2.25) 0.011 1.22 (0.79–1.88) 0.37
 Frail versus fit 1.58 (1.12–2.24) 0.009 1.26 (0.8–1.95) 0.32
Non-invasive ventilation/mechanical ventilation
 Vulnerable versus fit 0.94 (0.78–1.13) 0.51 1 (0.81–1.24) 0.99
 Frail versus fit 0.84 (0.7–1.02) 0.069 0.74 (0.58–0.91) 0.0096
Vasoactive drugs
 Vulnerable versus fit 0.99 (0.81–1.22) 0.93 1.09 (0.86–1.39) 0.47
 Frail versus fit 1.01 (0.84–1.25) 0.88 0.9 (0.7–1.15) 0.44
Renal replacement therapy
 Vulnerable versus fit 1.23 (0.81–1.86) 0.33 1.14 (0.7–1.87) 0.61
 Frail versus fit 1.62 (1.1–2.45) 0.014 1.01 (0.59–1.65) 0.98
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validity of the results. High quality data were collected pro-
spectively despite the strain on health care systems during 
the pandemic. In addition, this study focuses exclusively on 
elderly patients who were admitted to an intensive care unit.
Our study, however, has a number of limitations: (1) No 
data was collected about the pre-ICU triage process and 
as a result we do not know how many very old critically ill 
patients were denied ICU-admission. (2) it is an unblinded 
study as it is difficult to conduct a blinded study for frailty. 
(3) CFS is not a suitable tool to evaluate patients with 
either temporary disability (For example as a result of 
trauma or delirium) or stable long-term disabilities (for 
example, cerebral palsy), learning disability or autism; in 
the inclusion and exclusion criteria of our cohort these 
considerations were not explicitly acknowledged, which 
may have promoted selection bias. Furthermore, there 
are other health conditions, unrelated to frailty, that can 
limit activity that might lead to an artificially high CFS 
that does not reflect true frailty. (4) Another limitation of 
this study is the lack of functional outcome data. While 
we were able to investigate associations with mortal-
ity, the extent of morbidity in survivors remains unclear. 
(5) No younger patients were included in this study for 
comparison. (6) The list of co-morbidities recorded was 
incomplete as only the most prevalent were documented, 
other comorbidities such as haematologic disorders or 
those with immune deficiencies were not recorded. (7) It 
was not possible to assess frailty in 7% of patients due to 
insufficient information. (8) We did not record informa-
tion about the ethnic background, although it might be a 
potential confounding factor [28].
Our study does throw up some ethical dilemmas. There 
is an inter-relationship between high frailty scores and 
the unconscious bias of health care providers. For exam-
ple, a high CFS on admission could lead the ICU health 
care provider to treat a patient less aggressively and to set 
a limitation of therapy earlier in their illness. Thus, the 
knowledge of frailty implicitly influences the outcome of 
the patient. We raise this as a limitation of our study sim-
ilar to all studies describing outcomes in very old patients 
[10, 11, 24, 29], but also as a "caveat" for future studies. 
On the other hand, we know that frailty is the common, 
multifactorial endpoint of life, and therefore the presence 
of frailty per se (independent of its measurement) influ-
ences patient outcome and is thus a self-fulling prophecy.
Conclusion
Frailty provides relevant prognostic information in 
elderly COVID-19 patients in addition to age and comor-
bidities. Therefore, we recommend that a frailty assess-
ment should be routinely performed in these patients. 
In times of limited resources on the ICU, a frailty assess-
ment of elderly patients could be included in a holistic 
assessment of patients.
Fig. 2 Cumulative incidence of organ support and treatment limitations. a Combined mechanical ventilation (MV) and non-invasive ventilation. b 
Mechanical ventilation (MV). c Vasoactive drugs. d Non-invasive ventilation (NIV). e Treatment limitations. f Renal replacement therapy (RRT)
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